Table Info

Table 2.

List of viral proteins inferring with chemokine-cytokine response

Viral protein	Target	Effect	References
ICP34.5 or γ₁34.5	Inhibits eIF2α	Continued translation in HSV	He et al. [81] 1997
ICP34.5 or γ₁34.5	Binds to STING	Blocks STING’s transport from ER to Golgi, thereby induces IFN production	Christensen et al. [86] 2016
Us11	Quenches dsRNA and binds PKR	Inhibits PKR-induced arrest of protein translation	Peters et al. [82] 2002 Poppers et al. [83] 2000
ICP27	Binds TBK-STING	Prevents IRF3 activation and thereby IFN production	Christensen et al. [86] 2016
	IκBα	Reduced cytokine production	Kim et al. [108] 2008
	Suppresses IFN-induced STAT-1 phosphorylation	Dampen IFN signaling	Johnson et al. [95] 2008 Mogensen et al. [96] 2004
ICP0	Interferes with IRF3 and IRF7	Inhibits IFN-α/β mediated ISG expression	Mossman and Smiley [89] 2002 Mossman et al. [90] 2000 Shahnazaryan et al. [91] 2020 Härle et al. [92] 2002 Paladino et al. [93] 2010
ICP0	Binds MyD88, Mal	Interferes with IL-6 production	van Lint et al. [105] 2010
UsP7 induced by ICP0	Deubquitinated TRAF6, IKKγ	Reduced cytokine production	Daubeuf et al. [106] 2009
Vhs	Inhibits JAK-STAT pathway	Reduced IFN-1 production	Lin et al. [109] 2010

ICP34.5: infected cell protein 34.5; eIF2α: alpha subunit of eukaryotic initiation factor 2; HSV: herpes simplex virus; STING: stimulator of interferon genes; IFN: interferon; dsRNA: double stranded RNA; PKR: dsRNA-dependent protein kinase; IRF3: IFN-regulatory factor 3; TBK: TANK-binding kinase; IκBα: inhibitor of kappa B alpha; STAT-1: signal transducer and activator of transcription-1; ISG: IFN stimulated gene; MyD88: myeloid differentiation primary response protein 88; Mal: MyD88 adapter like; IL-6: interleukin-6; TRAF6: tumor necrosis factor receptor-associated factor 6; IKKγ: IκB kinase γ; Vhs: virion host shutoff; JAK: Janus kinase; ER: endoplasmic reticulum

Supplementary materials

The supplementary table for this article is available at: https://www.explorationpub.com/uploads/Article/file/1003148_sup_1.pdf.

Declarations

Author contributions

AM and SI equally contributed to: Investigation, Data curation, Resources, Formal analysis, Writing—original draft, Writing—review & editing. JG: Writing—original draft, Visualization. SB: Data curation, Formal analysis, Writing—original draft. PP: Data curation, Formal analysis, Writing—review & editing. DC: Conceptualization, Project administration, Writing—original draft, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

AM is supported by Presidency University, which received funding from DBT-BUILDER; DBT-FIST; and WB-DST. PP received funding from ICMR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Karimkhani C, Dellavalle RP, Coffeng LE, Flohr C, Hay RJ, Langan SM, et al. Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013. JAMA Dermatol. 2017;153:406–12. [DOI] [PubMed] [PMC]

Oakley A. Viral infections and the skin [Internet]. DermNet.; 2024 [cited 2023 May 15]. Available from: https://dermnetnz.org/topics/viral-skin-infections

Saleh W, Alharbi H, Cha S. Increased prevalence of erythema multiforme in patients with COVID-19 infection or vaccination. Sci Rep. 2024;14:2801. [DOI] [PubMed] [PMC]

Herpes simplex virus [Internet]. WHO; c2024 [cited 2023 Sep 18]. Available from: https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus

Billions worldwide living with herpes [Internet]. WHO; c2024 [cited 2023 Dec 22]. Available from: https://www.who.int/news/item/01-05-2020-billions-worldwide-living-with-herpes

James C, Harfouche M, Welton NJ, Turner KM, Abu-Raddad LJ, Gottlieb SL, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020;98:315–29. [DOI] [PubMed] [PMC]

McQuillan G, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14–49: United States, 2015–2016. NCHS Data Brief. 2018:1–8. [PubMed]

Khadr L, Harfouche M, Omori R, Schwarzer G, Chemaitelly H, Abu-Raddad LJ. The Epidemiology of Herpes Simplex Virus Type 1 in Asia: Systematic Review, Meta-analyses, and Meta-regressions. Clin Infect Dis. 2019;68:757–72. [DOI] [PubMed] [PMC]

Alareeki A, Osman AMM, Khandakji MN, Looker KJ, Harfouche M, Abu-Raddad LJ. Epidemiology of herpes simplex virus type 2 in Europe: systematic review, meta-analyses, and meta-regressions. Lancet Reg Health Eur. 2022;25:100558. [DOI] [PubMed] [PMC]

10.

Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol. 2021;19:110–21. [DOI] [PubMed] [PMC]

11.

NDe La Cruz NC, Möckel M, Wirtz L, Sunaoglu K, Malter W, Zinser M, et al. Ex Vivo Infection of Human Skin with Herpes Simplex Virus 1 Reveals Mechanical Wounds as Insufficient Entry Portals via the Skin Surface. J Virol. 2021;95:e0133821. [DOI] [PubMed] [PMC]

12.

Nag S, Sengupta M, Sarkar S, Ray Y, Chattopadhyay D, Sengupta M. Isolation, characterization and acyclovir susceptibility of herpes simplex virus isolates among immunocompromised patients. Indian J Sex Transm Dis AIDS. 2021;42:19–23. [DOI] [PubMed] [PMC]

13.

Bag P, Chattopadhyay D, Mukherjee H, Ojha D, Mandal N, Sarkar MC, et al. Anti-herpes virus activities of bioactive fraction and isolated pure constituent of Mallotus peltatus: an ethnomedicine from Andaman Islands. Virol J. 2012;9:98. [DOI] [PubMed] [PMC]

14.

O’Shea JJ, Gadina M, Siegel RM. 9 - Cytokines and Cytokine Receptors. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, editors. Clinical Immunology (Fifth Edition). London: Elsevier; 2019. pp. 127–55.e1.

15.

Karki R, Kanneganti TD. The ‘cytokine storm’: molecular mechanisms and therapeutic prospects. Trends Immunol. 2021;42:681–705. [DOI] [PubMed] [PMC]

16.

Carrillo JLM, García FPC, Coronado OG, García MAM, Cordero JFC. Physiology and Pathology of Innate Immune Response Against Pathogens. In: Rezaei N, editor. Physiology and Pathology of Immunology. Rijeka: IntechOpen; 2017.

17.

Luis Muñoz-Carrillo J, Francisco Contreras-Cordero J, Gutiérrez-Coronado O, Trinidad Villalobos-Gutiérrez P, Guillermo Ramos-Gracia L, Elizabeth Hernández-Reyes V. Cytokine Profiling Plays a Crucial Role in Activating Immune System to Clear Infectious Pathogens. In: Tyagi RK, Bisen PS, editors. Immune Response Activation and Immunomodulation. Rijeka: IntechOpen; 2018.

18.

Mogensen TH, Paludan SR. Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev. 2001;65:131–50. [DOI] [PubMed] [PMC]

19.

Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol. 2008;20:17–22. [DOI] [PubMed]

20.

Schulz O, Pichlmair A, Rehwinkel J, Rogers NC, Scheuner D, Kato H, et al. Protein kinase R contributes to immunity against specific viruses by regulating interferon mRNA integrity. Cell Host Microbe. 2010;7:354–61. [DOI] [PubMed] [PMC]

21.

Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006;7:131–7. [DOI] [PubMed]

22.

Zhou R, Liu L, Wang Y. Viral proteins recognized by different TLRs. J Med Virol. 2021;93:6116–23. [DOI] [PubMed]

23.

Xagorari A, Chlichlia K. Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol J. 2008;2:49–59. [DOI] [PubMed] [PMC]

24.

Kumari P, Russo AJ, Shivcharan S, Rathinam VA. AIM2 in health and disease: Inflammasome and beyond. Immunol Rev. 2020;297:83–95. [DOI] [PubMed] [PMC]

25.

Zheng W, Xu Q, Zhang Y, E X, Gao W, Zhang M, et al. Toll-like receptor-mediated innate immunity against Herpesviridae infection: a current perspective on viral infection signaling pathways. Virol J. 2020;17:192. Erratum in: Virol J. 2020;17:199. [DOI] [PubMed] [PMC]

26.

Sennikov SV, Temchura VV, Trufakin VA, Kozlov VA. Effects of granulocyte-macrophage colony-stimulating factor produced by intestinal epithelial cells on functional activity of hemopoietic stem cells. Bull Exp Biol Med. 2002;134:548–50. [DOI] [PubMed]

27.

González-Amaro R, García-Monzón C, García-Buey L, Moreno-Otero R, Alonso JL, Yagüe E, et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med. 1994;179:841–8. [DOI] [PubMed] [PMC]

28.

Aoki Y, Qiu D, Uyei A, Kao PN. Human airway epithelial cells express interleukin-2 in vitro. Am J Physiol. 1997;272:L276–86. [DOI] [PubMed]

29.

Walter MJ, Kajiwara N, Karanja P, Castro M, Holtzman MJ. Interleukin 12 p40 production by barrier epithelial cells during airway inflammation. J Exp Med. 2001;193:339–52. [DOI] [PubMed] [PMC]

30.

Burbach GJ, Naik SM, Harten JB, Liu L, Dithmar S, Grossniklaus H, et al. Interleukin-18 expression and modulation in human corneal epithelial cells. Curr Eye Res. 2001;23:64–8. [DOI] [PubMed]

31.

Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176:1908–15. [DOI] [PubMed]

32.

Yannam GR, Gutti T, Poluektova LY. IL-23 in infections, inflammation, autoimmunity and cancer: possible role in HIV-1 and AIDS. J Neuroimmune Pharmacol. 2012;7:95–112. [DOI] [PubMed] [PMC]

33.

Cotton JA, Platnich JM, Muruve DA, Jijon HB, Buret AG, Beck PL. Interleukin-8 in gastrointestinal inflammation and malignancy: induction and clinical consequences. Int J Interferon Cytokine Mediator Res. 2016;8:13–34. [DOI]

34.

Yin Y, Favoreel HW. Herpesviruses and the Type III Interferon System. Virol Sin. 2021;36:577–87. [DOI] [PubMed] [PMC]

35.

Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. 2011;17:2619–27. [DOI] [PubMed]

36.

Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998;161:1947–53. [PubMed]

37.

Le Bon A, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C, et al. Direct stimulation of T cells by type I IFN enhances the CD8⁺ T cell response during cross-priming. J Immunol. 2006;176:4682–9. [DOI] [PubMed]

38.

Freeman BE, Raué HP, Hill AB, Slifka MK. Cytokine-Mediated Activation of NK Cells during Viral Infection. J Virol. 2015;89:7922–31. [DOI] [PubMed] [PMC]

39.

Ito H, Esashi E, Akiyama T, Inoue J, Miyajima A. IL-18 produced by thymic epithelial cells induces development of dendritic cells with CD11b in the fetal thymus. Int Immunol. 2006;18:1253–63. [DOI] [PubMed]

40.

Striz I, Brabcova E, Kolesar L, Sekerkova A. Cytokine networking of innate immunity cells: a potential target of therapy. Clin Sci (Lond). 2014;126:593–612. [DOI] [PubMed]

41.

Seo SH, Webster RG. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J Virol. 2002;76:1071–6. [DOI] [PubMed] [PMC]

42.

Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–69. Erratum in: Nat Rev Immunol. 2010;10:460. [DOI] [PubMed] [PMC]

43.

Eskilsson A, Mirrasekhian E, Dufour S, Schwaninger M, Engblom D, Blomqvist A. Immune-induced fever is mediated by IL-6 receptors on brain endothelial cells coupled to STAT3-dependent induction of brain endothelial prostaglandin synthesis. J Neurosci. 2014;34:15957–61. [DOI] [PubMed] [PMC]

44.

Di Paolo NC, Shayakhmetov DM. Interleukin 1α and the inflammatory process. Nat Immunol. 2016;17:906–13. [DOI] [PubMed] [PMC]

45.

Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117:1162–72. [DOI] [PubMed]

46.

Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T, Goldeck M, et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5’-diphosphates. Nature. 2014;514:372–5. [DOI] [PubMed] [PMC]

47.

Letterio JJ, Roberts AB. TGF-β: a critical modulator of immune cell function. Clin Immunol Immunopathol. 1997;84:244–50. [DOI] [PubMed]

48.

Ovaere P, Lippens S, Vandenabeele P, Declercq W. The emerging roles of serine protease cascades in the epidermis. Trends Biochem Sci. 2009;34:453–63. [DOI] [PubMed]

49.

Hsu YC, Li L, Fuchs E. Emerging interactions between skin stem cells and their niches. Nat Med. 2014;20:847–56. [DOI] [PubMed] [PMC]

50.

Woodley DT. Distinct Fibroblasts in the Papillary and Reticular Dermis: Implications for Wound Healing. Dermatol Clin. 2017;35:95–100. [DOI] [PubMed]

51.

Nguyen AV, Soulika AM. The Dynamics of the Skin’s Immune System. Int J Mol Sci. 2019;20:1811. [DOI] [PubMed] [PMC]

52.

Cildir G, Akıncılar SC, Tergaonkar V. Chronic adipose tissue inflammation: all immune cells on the stage. Trends Mol Med. 2013;19:487–500. [DOI] [PubMed]

53.

Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol. 2008;17:1063–72. [DOI] [PubMed]

54.

Mikloska Z, Danis VA, Adams S, Lloyd AR, Adrian DL, Cunningham AL. In vivo production of cytokines and β (C-C) chemokines in human recurrent herpes simplex lesions—do herpes simplex virus-infected keratinocytes contribute to their production? J Infect Dis. 1998;177:827–38. [DOI] [PubMed]

55.

Cunningham AL, Turner RR, Miller AC, Para MF, Merigan TC. Evolution of recurrent herpes simplex lesions. An immunohistologic study. J Clin Invest. 1985;75:226–33. [DOI] [PubMed] [PMC]

56.

Bertram KM, Truong NR, Smith JB, Kim M, Sandgren KJ, Feng KL, et al. Herpes Simplex Virus type 1 infects Langerhans cells and the novel epidermal dendritic cell, Epi-cDC2s, via different entry pathways. PLoS Pathog. 2021;17:e1009536. [DOI] [PubMed] [PMC]

57.

Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45:27–37. [DOI] [PubMed] [PMC]

58.

Sokol CL, Luster AD. The chemokine system in innate immunity. Cold Spring Harb Perspect Biol. 2015;7:a016303. [DOI] [PubMed] [PMC]

59.

Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014;5:491. [DOI] [PubMed] [PMC]

60.

Smith JB, Herbert JJ, Truong NR, Cunningham AL. Cytokines and chemokines: The vital role they play in herpes simplex virus mucosal immunology. Front Immunol. 2022;13:936235. [DOI] [PubMed] [PMC]

61.

Sun S, Jin L, Zheng Y, Zhu J. Modeling human HSV infection via a vascularized immune-competent skin-on-chip platform. Nat Commun. 2022;13:5481. [DOI] [PubMed] [PMC]

62.

Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5:987–95. [DOI] [PubMed]

63.

Shao Y, Zhang W, Dong X, Liu W, Zhang Ch, Zhang J, et al. Keratinocytes play a role in the immunity to Herpes simplex virus type 2 infection. Acta Virol. 2010;54:261–7. [DOI] [PubMed]

64.

Oliveira-Nascimento L, Massari P, Wetzler LM. The Role of TLR2 in Infection and Immunity. Front Immunol. 2012;3:79. [DOI] [PubMed] [PMC]

65.

Purwar R, Wittmann M, Zwirner J, Oppermann M, Kracht M, Dittrich-Breiholz O, et al. Induction of C3 and CCL2 by C3a in keratinocytes: a novel autocrine amplification loop of inflammatory skin reactions. J Immunol. 2006;177:4444–50. [DOI] [PubMed]

66.

Cunningham AL, Noble JR. Role of keratinocytes in human recurrent herpetic lesions. Ability to present herpes simplex virus antigen and act as targets for T lymphocyte cytotoxicity in vitro. J Clin Invest. 1989;83:490–6. [DOI] [PubMed] [PMC]

67.

Kajita AI, Morizane S, Takiguchi T, Yamamoto T, Yamada M, Iwatsuki K. Interferon-Gamma Enhances TLR3 Expression and Anti-Viral Activity in Keratinocytes. J Invest Dermatol. 2015;135:2005–11. [DOI] [PubMed]

68.

Malmgaard L, Paludan SR, Mogensen SC, Ellermann-Eriksen S. Herpes simplex virus type 2 induces secretion of IL-12 by macrophages through a mechanism involving NF-κB. J Gen Virol. 2000;81:3011–20. [DOI] [PubMed]

69.

Ellermann-Eriksen S. Macrophages and cytokines in the early defence against herpes simplex virus. Virol J. 2005;2:59. [DOI] [PubMed] [PMC]

70.

Milora KA, Miller SL, Sanmiguel JC, Jensen LE. Interleukin-1α released from HSV-1-infected keratinocytes acts as a functional alarmin in the skin. Nat Commun. 2014;5:5230. [DOI] [PubMed] [PMC]

71.

Nandakumar S, Woolard SN, Yuan D, Rouse BT, Kumaraguru U. Natural killer cells as novel helpers in anti-herpes simplex virus immune response. J Virol. 2008;82:10820–31. [DOI] [PubMed] [PMC]

72.

Mikloska Z, Kesson AM, Penfold ME, Cunningham AL. Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-γ. J Infect Dis. 1996;173:7–17. [DOI] [PubMed]

73.

Schiffer JT, Corey L. Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med. 2013;19:280–8. [DOI] [PubMed] [PMC]

74.

Philip DT, Goins NM, Catanzaro NJ, Misumi I, Whitmire JK, Atkins HM, et al. Interferon lambda restricts herpes simplex virus skin disease by suppressing neutrophil-mediated pathology. mBio. 2024;15:e02623-23. [DOI] [PubMed] [PMC]

75.

Sodroski CN, Knipe DM. Nuclear interferon-stimulated gene product maintains heterochromatin on the herpes simplex viral genome to limit lytic infection. Proc Natl Acad Sci U S A. 2023;120:e2310996120. [DOI] [PubMed] [PMC]

76.

Jia M, Wang Y, Wang J, Qin D, Wang M, Chai L, et al. Myristic acid as a checkpoint to regulate STING-dependent autophagy and interferon responses by promoting N-myristoylation. Nat Commun. 2023;14:660. [DOI] [PubMed] [PMC]

77.

Chattopadhyay D, Mukhopadhyay A, Ojha D, Sadhukhan P, Dutta S. Immuno-metabolic changes in herpes virus infection. Cytokine. 2018;112:52–62. [DOI] [PubMed]

78.

Zhu S, Viejo-Borbolla A. Pathogenesis and virulence of herpes simplex virus. Virulence. 2021;12:2670–702. [DOI] [PubMed] [PMC]

79.

Malmgaard L, Melchjorsen J, Bowie AG, Mogensen SC, Paludan SR. Viral activation of macrophages through TLR-dependent and -independent pathways. J Immunol. 2004;173:6890–8. [DOI] [PubMed]

80.

Chou J, Chen JJ, Gross M, Roizman B. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. Proc Natl Acad Sci U S A. 1995;92:10516–20. [DOI] [PubMed] [PMC]

81.

He B, Gross M, Roizman B. The γ₁34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A. 1997;94:843–8. [DOI] [PubMed] [PMC]

82.

Peters GA, Khoo D, Mohr I, Sen GC. Inhibition of PACT-mediated activation of PKR by the herpes simplex virus type 1 Us11 protein. J Virol. 2002;76:11054–64. [DOI] [PubMed] [PMC]

83.

Poppers J, Mulvey M, Khoo D, Mohr I. Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein. J Virol. 2000;74:11215–21. [DOI] [PubMed] [PMC]

84.

Sharma N, Wang C, Kessler P, Sen GC. Herpes simplex virus 1 evades cellular antiviral response by inducing microRNA-24, which attenuates STING synthesis. PLoS Pathog. 2021;17:e1009950. [DOI] [PubMed] [PMC]

85.

Pan S, Liu X, Ma Y, Cao Y, He B. Herpes Simplex Virus 1 γ₁34.5 Protein Inhibits STING Activation That Restricts Viral Replication. J Virol. 2018;92:10.1128/jvi.01015-18. [DOI] [PubMed] [PMC]

86.

Christensen MH, Jensen SB, Miettinen JJ, Luecke S, Prabakaran T, Reinert LS, et al. HSV-1 ICP27 targets the TBK1-activated STING signalsome to inhibit virus-induced type I IFN expression. EMBO J. 2016;35:1385–99. [DOI] [PubMed] [PMC]

87.

Xie Y, He S, Wang J. MicroRNA-373 facilitates HSV-1 replication through suppression of type I IFN response by targeting IRF1. Biomed Pharmacother. 2018;97:1409–16. [DOI] [PubMed]

88.

Cai M, Liao Z, Zou X, Xu Z, Wang Y, Li T, et al. Herpes Simplex Virus 1 UL2 Inhibits the TNF-α–Mediated NF-κB Activity by Interacting With p65/p50. Front Immunol. 2020;11:549. [DOI] [PubMed] [PMC]

89.

Mossman KL, Smiley JR. Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication. J Virol. 2002;76:1995–8. [DOI] [PubMed] [PMC]

90.

Mossman KL, Saffran HA, Smiley JR. Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J Virol. 2000;74:2052–6. [DOI] [PubMed] [PMC]

91.

Shahnazaryan D, Khalil R, Wynne C, Jefferies CA, Ní Gabhann-Dromgoole J, Murphy CC. Herpes simplex virus 1 targets IRF7 via ICP0 to limit type I IFN induction. Sci Rep. 2020;10:22216. [DOI] [PubMed] [PMC]

92.

Härle P, Sainz B Jr, Carr DJ, Halford WP. The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-α/β. Virology. 2002;293:295–304. [DOI] [PubMed]

93.

Paladino P, Collins SE, Mossman KL. Cellular localization of the herpes simplex virus ICP0 protein dictates its ability to block IRF3-mediated innate immune responses. PLoS One. 2010;5:e10428. [DOI] [PubMed] [PMC]

94.

Lanfranca MP, Mostafa HH, Davido DJ. HSV-1 ICP0: An E3 Ubiquitin Ligase That Counteracts Host Intrinsic and Innate Immunity. Cells. 2014;3:438–54. [DOI] [PubMed] [PMC]

95.

Johnson KE, Song B, Knipe DM. Role for herpes simplex virus 1 ICP27 in the inhibition of type I interferon signaling. Virology. 2008;374:487–94. [DOI] [PubMed] [PMC]

96.

Mogensen TH, Melchjorsen J, Malmgaard L, Casola A, Paludan SR. Suppression of proinflammatory cytokine expression by herpes simplex virus type 1. J Virol. 2004;78:5883–90. [DOI] [PubMed] [PMC]

97.

Melchjorsen J, Matikainen S, Paludan SR. Activation and evasion of innate antiviral immunity by herpes simplex virus. Viruses. 2009;1:737–59. [DOI] [PubMed] [PMC]

98.

Duerst RJ, Morrison LA. Herpes simplex virus 2 virion host shutoff protein interferes with type I interferon production and responsiveness. Virology. 2004;322:158–67. [DOI] [PubMed]

99.

Murphy JA, Duerst RJ, Smith TJ, Morrison LA. Herpes simplex virus type 2 virion host shutoff protein regulates alpha/beta interferon but not adaptive immune responses during primary infection in vivo. J Virol. 2003;77:9337–45. [DOI] [PubMed] [PMC]

100.

Ferreira VH, Nazli A, Mossman KL, Kaushic C. Proinflammatory cytokines and chemokines – but not interferon-β – produced in response to HSV-2 in primary human genital epithelial cells are associated with viral replication and the presence of the virion host shutoff protein. Am J Reprod Immunol. 2013;70:199–212. [DOI] [PubMed]

101.

Yokota S, Yokosawa N, Okabayashi T, Suzutani T, Miura S, Jimbow K, et al. Induction of suppressor of cytokine signaling-3 by herpes simplex virus type 1 contributes to inhibition of the interferon signaling pathway. J Virol. 2004;78:6282–6. [DOI] [PubMed] [PMC]

102.

Frey KG, Ahmed CM, Dabelic R, Jager LD, Noon-Song EN, Haider SM, et al. HSV-1-induced SOCS-1 expression in keratinocytes: use of a SOCS-1 antagonist to block a novel mechanism of viral immune evasion. J Immunol. 2009;183:1253–62. [DOI] [PubMed] [PMC]

103.

Pasieka TJ, Lu B, Crosby SD, Wylie KM, Morrison LA, Alexander DE, et al. Herpes simplex virus virion host shutoff attenuates establishment of the antiviral state. J Virol. 2008;82:5527–35. [DOI] [PubMed] [PMC]

104.

Orzalli MH, Broekema NM, Knipe DM. Relative Contributions of Herpes Simplex Virus 1 ICP0 and vhs to Loss of Cellular IFI16 Vary in Different Human Cell Types. J Virol. 2016;90:8351–9. [DOI] [PubMed] [PMC]

105.

van Lint AL, Murawski MR, Goodbody RE, Severa M, Fitzgerald KA, Finberg RW, et al. Herpes simplex virus immediate-early ICP0 protein inhibits Toll-like receptor 2-dependent inflammatory responses and NF-κB signaling. J Virol. 2010;84:10802–11. [DOI] [PubMed] [PMC]

106.

Daubeuf S, Singh D, Tan Y, Liu H, Federoff HJ, Bowers WJ, et al. HSV ICP0 recruits USP7 to modulate TLR-mediated innate response. Blood. 2009;113:3264–75. [DOI] [PubMed] [PMC]

107.

Melchjorsen J, Sirén J, Julkunen I, Paludan SR, Matikainen S. Induction of cytokine expression by herpes simplex virus in human monocyte-derived macrophages and dendritic cells is dependent on virus replication and is counteracted by ICP27 targeting NF-κB and IRF-3. J Gen Virol. 2006;87:1099–108. [DOI] [PubMed]

108.

Kim JC, Lee SY, Kim SY, Kim JK, Kim HJ, Lee HM, et al. HSV-1 ICP27 suppresses NF-κB activity by stabilizing IκBα. FEBS Lett. 2008;582:2371–6. [DOI] [PubMed]

109.

Lin HW, Hsu WL, Chang YY, Jan MS, Wong ML, Chang TJ. Role of the UL41 protein of pseudorabies virus in host shutoff, pathogenesis and induction of TNF-α expression. J Vet Med Sci. 2010;72:1179–87. [DOI] [PubMed]

110.

Li Z, Feng Z, Fang Z, Chen J, Chen W, Liang W, et al. Herpes simplex virus type I glycoprotein L evades host antiviral innate immunity by abrogating the nuclear translocation of phosphorylated NF-κB sub-unit p65. Front Microbiol. 2023;14:1178249. [DOI] [PubMed] [PMC]

111.

Broekema N, Mertens ME, Angelova M, Orzalli MH, Oh HS, Knipe DM. Herpes simplex virus infected cell protein 8 is required for viral inhibition of the cGAS pathway. Virology. 2023;585:34–41. [DOI] [PubMed]